## nature portfolio

Corresponding author(s):	Aiden Doherty
Last updated by author(s):	Nov 27, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
C -	トつ	t١	ct	ics
	п		<b>&gt;</b> 1	11 >

For a	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement		
	A stateme	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
$\boxtimes$		cical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.		
	A description of all covariates tested			
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)  AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
$\boxtimes$	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated			
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code				
Polic	cy information a	about <u>availability of computer code</u>		
Da	ta collection	No software was used		
Da	ta analysis	All the code for data processing, training the model and evaluation can be found on Github. https://github.com/OxWearables/asleep		

## Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The UK Biobank accelerometery dataset used for training can be requested by application: https://www.ukbiobank.ac.uk/enable-your-research/register.

The Raine dataset can be requested by application: https://rainestudy.org.au/information-for-researchers/project-application-process/

All the other data can be requested by contacting the authors.				
Research invol	g human participants, their data, or biological material			
•	udies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentarace, ethnicity and racism</u> .	ation),		
Reporting on sex and	Information regarding sex was obtained for each dataset used where possible.			
	The findings apply to both males and females.			
	Sex was determined from self-reporting.			
	Overall, around data samples from 39,000 females and 28,000 males were included in the association analysis.			
Reporting on race, e	ity, or Relevant social groupings were collected via self-report at the baseline study, which is specified in Supplement Sect	tion 7.		
other socially relevar groupings	We adjusted for confounders in our association analysis, which is also specified in Supplement Section 7.			
Population character	Mostly, data from healthy participants were obtained. One dataset consists of patients from a sleep clinics.			
Recruitment	This paper performs secondary data analysis and did not recruit any participant.	This paper performs secondary data analysis and did not recruit any participant.		
Ethics oversight	The data used (project ref 21/NW/0157) is covered by ethical approval from the NHS National Research Ethics.	The data used (project ref 21/NW/0157) is covered by ethical approval from the NHS National Research Ethics.		
Note that full information	he approval of the study protocol must also be provided in the manuscript.			
Field-sneci	creporting			
· · · · · · · · · · · · · · · · · · ·	v that is the best fit for your research. If you are not sure, read the appropriate sections before making your sel	lection		
Life sciences	Behavioural & social sciences	rection.		
	ent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scienc	study design			
All studies must disclos	these points even when the disclosure is negative.			
Sample size Th	The sample size has already been determined by the collected data as this paper performs secondary data analysis.			
Data exclusions We	We excluded data from participants with low-quality data based on missing covariates and prevalent diseases.			
Replication Th	The results of this paper have been verified by at least two authors successfully.			

## Reporting for specific materials, systems and methods

Randomization

Blinding

NA

NA

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimen	ntal systems Me	ethods
n/a Involved in the study	n/a	Involved in the study
Antibodies		ChIP-seq
Eukaryotic cell lines		Flow cytometry
Palaeontology and a	rchaeology	MRI-based neuroimaging
Animals and other or	rganisms	
Clinical data		
Dual use research of	concern	
'		
Plants		
Seed stocks	NA	
Novel plant genotypes	NA	
Authentication	NA	
Novel plant genotypes	NA	